Skip to Main Content

Paper Details

Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).
Crit Care Med
135
2019
Antiprogrammed Cell Death-Ligand 1 Antibody, BMS-936559, Participants, Sepsis, acute renal injury, acute respiratory failure, antiprogrammed cell death-ligand 1, cytokine storm, human, human leukocyte antigen-DR, hypercytokinemia, hypotension, lymphocyte, monocyte, monocyte human leukocyte antigen-DR, organ dysfunction, participants, patients, programmed cell death protein-1, programmed cell death-ligand 1, sepsis
Author NameAffiliation
Sachin YendeVeterans Affairs Pittsburgh Healthcare System
Sachin YendeUniversity of Pittsburgh School of Medicine
Derek C AngusUniversity of Pittsburgh School of Medicine
Lyle L MoldawerUniversity of Florida College of Medicine
Lyle L MoldawerUniversity of Florida College of Medicine
Greg S MartinEmory University
Craig M CoopersmithEmory University
Scott C BrakenridgeUniversity of Florida College of Medicine
Pauline K ParkUniversity of Michigan ann arbor
  • 1 - 9

Datasets

Release 1.2